164 related articles for article (PubMed ID: 24387284)
1. The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®.
Staudacher AH; Al-Ejeh F; Fraser CK; Darby JM; Roder DM; Ruszkiewicz A; Manavis J; Brown MP
EJNMMI Res; 2014 Jan; 4(1):2. PubMed ID: 24387284
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.
Al-Ejeh F; Darby JM; Brown MP
PLoS One; 2009; 4(2):e4630. PubMed ID: 19247485
[TBL] [Abstract][Full Text] [Related]
3. APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.
Al-Ejeh F; Darby JM; Tsopelas C; Smyth D; Manavis J; Brown MP
PLoS One; 2009; 4(2):e4558. PubMed ID: 19247492
[TBL] [Abstract][Full Text] [Related]
4. Postchemotherapy and tumor-selective targeting with the La-specific DAB4 monoclonal antibody relates to apoptotic cell clearance.
Al-Ejeh F; Staudacher AH; Smyth DR; Darby JM; Denoyer D; Tsopelas C; Hicks RJ; Brown MP
J Nucl Med; 2014 May; 55(5):772-9. PubMed ID: 24676755
[TBL] [Abstract][Full Text] [Related]
5. Targeted α-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation.
Staudacher AH; Bezak E; Borysenko A; Brown MP
Nucl Med Commun; 2014 Dec; 35(12):1284-90. PubMed ID: 25192189
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
7. Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models.
Liapis V; Tieu W; Wittwer NL; Gargett T; Evdokiou A; Takhar P; Rudd SE; Donnelly PS; Brown MP; Staudacher AH
Mol Imaging Biol; 2021 Dec; 23(6):914-928. PubMed ID: 34231102
[TBL] [Abstract][Full Text] [Related]
8. APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective
Staudacher AH; Li Y; Liapis V; Hou JJC; Chin D; Dolezal O; Adams TE; van Berkel PH; Brown MP
Mol Cancer Ther; 2019 Feb; 18(2):335-345. PubMed ID: 30413648
[TBL] [Abstract][Full Text] [Related]
9. Tumour-associated macrophages process drug and radio-conjugates of the dead tumour cell-targeting APOMAB® antibody.
Staudacher AH; Liapis V; Tieu W; Wittwer NL; Brown MP
J Control Release; 2020 Nov; 327():779-787. PubMed ID: 32946876
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.
Mortensen AC; Spiegelberg D; Haylock AK; Lundqvist H; Nestor M
Int J Oncol; 2018 Jun; 52(6):1875-1885. PubMed ID: 29658563
[TBL] [Abstract][Full Text] [Related]
11. Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB®.
Staudacher AH; Liapis V; Wittwer NL; Tieu W; Lam HC; Leusen J; Brown MP
Biomed Pharmacother; 2022 Jul; 151():113090. PubMed ID: 35567988
[TBL] [Abstract][Full Text] [Related]
12. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
Lindenblatt D; Terraneo N; Pellegrini G; Cohrs S; Spycher PR; Vukovic D; Béhé M; Schibli R; Grünberg J
BMC Cancer; 2018 Sep; 18(1):922. PubMed ID: 30253737
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
14. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
15. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
16. In vivo targeting of dead tumor cells in a murine tumor model using a monoclonal antibody specific for the La autoantigen.
Al-Ejeh F; Darby JM; Pensa K; Diener KR; Hayball JD; Brown MP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5519s-5527s. PubMed ID: 17875784
[TBL] [Abstract][Full Text] [Related]
17. The La autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs.
Al-Ejeh F; Darby JM; Brown MP
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5509s-5518s. PubMed ID: 17875783
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.
Meredith RF; Alvarez RD; Partridge EE; Khazaeli MB; Lin CY; Macey DJ; Austin JM; Kilgore LC; Grizzle WE; Schlom J; LoBuglio AF
Cancer Biother Radiopharm; 2001 Aug; 16(4):305-15. PubMed ID: 11603001
[TBL] [Abstract][Full Text] [Related]
19. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
20. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
